

A
HD#1 PB (Gamma)
Chain
TRGV02
TRGV03
TRGV04
TRGV05
TRGV08
TRGV09
Counts
Length
HD#1 PB (Delta)
Chain
TRDV01
TRDV02
TRDV05
TRDV08
Counts
Length
HD#1 DOT (Gamma)
Chain
TRGV02
TRGV03
TRGV04
TRGV05
TRGV08
TRGV09
Counts
Length
HD#1 PB (Delta)
Chain
TRDV01
TRDV02
TRDV03
TRDV05
TRDV07
TRDV09
Counts
Length
B
HD#2 PB (Gamma)
Chain
TRGV02
TRGV03
TRGV04
TRGV05
TRGV08
TRGV09
Counts
Length
HD#2 PB (Delta)
Chain
TRDV01
TRDV02
TRDV03
TRDV04
TRDV05
TRDV08
Counts
Length
HD#2 DOT (Gamma)
Chain
TRGV02
TRGV03
TRGV04
TRGV05
TRGV08
TRGV09
Counts
Length
HD#2 DOT (Delta)
Chain
TRDV01
TRDV02
TRDV03
TRDV05
TRDV07
TRDV08
Counts
Length

FIGURE 1





FIGURE 1 (contd.)

A


100
80
60
40
20
0
Ann V+ cells (%)
CD27+
CD27-
HD#5
HD#6

B



NCR expression
100
80
60
40
20
0
Gated on CD3+V61+
CD27+
CD27-
NKp30
NKp44

FIGURE 2




A
Donor 1 clones
Donor 2 clones
Donor 3 clones
Donor 4 clones
Ann V+ cells (%)
0
20
40
60
80
100
B
CTR
+ anti Vδ1(TCS-1)
HD#1
HD#2
HD#3
HD#4

FIGURE 3

A


AML cell lines
Ann V+ cells (%)
100
80
60
40
20
0
THP-1
HEL
AML-193
MV4-11
HL-60
U-937
OCI-AML3
KASUMI-1
KG1
HD#1
HD#2
HD#3
HD#4

B




AML primary samples
Ann V+ cells (%)
100
80
60
40
20
0
AML-A
AML-B
AML-C
AML-D
Healthy PBMCs
CTR
VD1

FIGURE 4

C



D





FIGURE 4 (contd.)

E



F




FIGURE 4 (contd.)



AML
MV4-11
Kasumi-1
HL-60
ALL
NALM-6
NHL
Raji
Healthy PBMCs
LK008
LK009
% Lysis
E:T Ratio
0:1
1:1
2:1
5:1
10:1

FIGURE 5





A
Primary AML cells
(1x 10^6 cells)
i.b.m
VD1 cells or PBS
(2 x 10^7 cells)
tail i.v
Tumor burden
(Weekly bleedings)
Survival
assessement
NSGS
7-10
Day 0
+ 1
+ 8
+ 15
Sublethal irradiation
(200 – 225 rad)
Tumor trigger in the blood
(>100 tumor cells/mL)
B
KG-1 AML cells
(2 x 10^6 cells)
tail i.v
VD1 cells or PBS
(2 x 10^7 cells)
tail i.v
Tumor burden
(Weekly bleedings)
Survival
assessement
NSG
Day 0
10
17
24
Sublethal irradiation
(200 – 225 rad)
C
HEL AML
(1 x 10^4 cells)
i.b.m
VD1 cells or PBS
(2 x 10^7 cells)
tail i.v
NRGS
7-10
Survival
assessement
Day 0
+ 1
+ 8
+ 15
Tumor burden
(Weekly bleedings)
Sublethal irradiation
(225 – 250 rad)
Tumor trigger in the blood
(>100 tumor cells/mL)
CTR
VD1
Survival (%)
100
80
60
40
20
0
p< 0.05
0 5 10 15 18 20 22 24 26 28 30
Days after tumor trigger

FIGURE 6










FIGURE 6 (contd.)

G



H



I




FIGURE 6 (contd.)



A
***
ns
CTR
Doxo+Cyta
DOT
Ann V+ cells (%)
100
80
60
40
20
0
wt HEL
CR HEL
B
Tumor Cells (#)
3.5 x 10^6
3.0 x 10^6
2.5 x 10^6
2.0 x 10^6
6.0 x 10^3
0
Pre-treatment
Post-treatment
C
-DOT
5:1
10:1
Ann V+ cells (%)
100
80
60
40
20
0
NT HEL
DT HEL

FIGURE 7




FIGURE 7 (contd.)



HL-60 (2ng/ml IL-15)
% Sytox+ (of CTV+)
100
80
60
40
20
0
Background 1
C1 (0h-48h)
Background 2
C2 (48h-120h)
C1 - Tumour cell challenge 1
C2 - Tumour cell challenge 2

FIGURE 8

A



GDX012
TCR stim (5µg/ml)
MIP-1b / CCL4
IL-16
MIP-1a / CCL3
IFN g
GM-CSF
IL-2
TNF-a
M-CSF
MCP-1 / CCL2
BLC / CXCL3
TNF-b
IL-21
MIG / CXCL9
IL-5
IL-15
IL-13
RANTES/ CCL5
IL-22
IL-17a
IL-4
IL-6
10
100
1000
10000
pg / 10^6 cells / hour

FIGURE 9




FIGURE 9 (contd.)

C




FIGURE 9 (contd.)




FIGURE 9 (contd.)





Cytotoxicity (NALM-6 + B cell)
% Sytox+
60
40
20
0
1:1
2:1
5:1
10:1
E:T Ratio
B cell
B cell + GDX012
NALM-6
NALM-6 + GDX012

FIGURE 10





*N.D= not detected

FIGURE 11



Tumour burden (bioluminescence)
7×10⁹
6×10⁹
5×10⁹
4×10⁹
3×10⁹
2×10⁹
1×10⁹
0
14
21
28
Time (days)
Control
GDX012

FIGURE 12




FIGURE 12 (contd.)



GDX012 in the bone marrow:
study end point
huTCRγδ
huCD45
0.14
% TCRγδ+ cells
(% of live)
0.16
0.12
0.08
0.04
0.00
Control
GDX012

FIGURE 13




FIGURE 13 (contd.)